Methotrexate
Approved · EMAAlso known as 4-amino-10-methylfolic acid, 4-amino-N(10)-methylpteroylglutamic acid, Amethopterin, Jylamvo+13 more
4-amino-10-methylfolic acid, 4-amino-N(10)-methylpteroylglutamic acid, Amethopterin, Jylamvo, MTX, MTX - methotrexate, Otrexup, Rasuvo, RediTrex, Trexall, Xatmep, methylaminopterin, Methotrexat, Metotrexato, Méthotrexate, Methotrexate Sodium, Methotrexatum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Targeting immunometabolism as an anti-inflammatory strategy.
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Preventing and Managing Toxicities of High-Dose Methotrexate.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: In rheumatological and dermatological diseases Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in… Show full indicationShow less
In rheumatological and dermatological diseases Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients. In oncology Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.
Indication: Nordimet is indicated for the treatment of: active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the… Show full indicationShow less
Nordimet is indicated for the treatment of: active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate, moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Use of Letrozole in the Treatment of Early Ectopic Pregnancy
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- Annals of the rheumatic diseases2
- The British journal of dermatology2
- The New England journal of medicine2
- American heart journal1
- Annals of internal medicine1
- Cell research1
- Amital H2
- Bernasconi C2
- Conaghan PG2
- Dougados M2
- Huizinga TW2
- Kissel K2
- Mola EM2
- Ortonne JP2
- Brigham and Women's Hospital1
- Catholic Children's Hospital1
- Center for Rheumatology1
- Charité University Medicine1
- Cochin Hospital1
- Comprehensive Center for Inflammation Medicine1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Methotrexate in the shared literature.
Studied across 3 of the same disease areas as Methotrexate in the shared literature.
Studied across 3 of the same disease areas as Methotrexate in the shared literature.
Studied across 3 of the same disease areas as Methotrexate in the shared literature.
Studied across 2 of the same disease areas as Methotrexate in the shared literature.
Studied across 2 of the same disease areas as Methotrexate in the shared literature.
Studied across 2 of the same disease areas as Methotrexate in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.